[
    [
        {
            "time": "2019-03-21",
            "original_text": "Biogen’s Big Bet in Alzheimer’s Disease Is a Bust",
            "features": {
                "keywords": [
                    "Biogen",
                    "Alzheimer’s",
                    "Bust"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Biogen’s Big Bet in Alzheimer’s Disease Is a Bust",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "Alkermes Focuses on Pipeline, Depends on Partners for Funds",
            "features": {
                "keywords": [
                    "Alkermes",
                    "Pipeline",
                    "Partners",
                    "Funds"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Alkermes Focuses on Pipeline, Depends on Partners for Funds",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-21",
            "original_text": "Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial",
            "features": {
                "keywords": [
                    "Biogen",
                    "shares",
                    "tank",
                    "Alzheimer’s",
                    "drug",
                    "trial"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial",
                "Correlation": 10,
                "Sentiment": 1,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-03-20",
            "original_text": "9 High-Margin Stocks Seen Leading in Fed's New Dovish Era",
            "features": {
                "keywords": [
                    "High-Margin",
                    "Stocks",
                    "Fed",
                    "Dovish",
                    "Era"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "economy",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "9 High-Margin Stocks Seen Leading in Fed's New Dovish Era",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]